Author Archives: Gastroenterology Journal

Artificial intelligence (AI) has arrived and it will directly impact how we assess, monitor, and manage inflammatory bowel diseases (IBD). Advances in the machine learning methodologies that power AI have produced astounding results for replicating exp… Continue reading →

Early diagnosis and the optimal control of inflammation, with a continuous cycle of assessment, treatment, monitoring and adjustment of therapy is best practice for the management of IBD. However, patients express frustration with ongoing challenging s… Continue reading →

Breaking through the biologic therapy efficacy plateau for inflammatory bowel disease requires the strategic development of personalized biomarkers in the tight control model. After risk stratification early in the disease course, targeted serial monit… Continue reading →

Outcomes for patients starting a new treatment for inflammatory bowel disease (IBD) are characterised by uncertainty of treatment response. Although it is natural to hope that new treatments will be characterised by better efficacy, remission is still … Continue reading →

Gastroenterologists will be all too familiar with the difficult decisions that managing IBD often presents. How aggressively should I treat this patient? Do I expect them to have a mild or aggressive form of disease? Do they need a biologic? If so, whi… Continue reading →

Inflammatory bowel disease is characterised by significant interindividual heterogeneity. With a wider selection of pharmacological and non-pharmacological interventions available and in advanced developmental stages, a priority for the coming decade i… Continue reading →

The incidence of inflammatory bowel disease (IBD) is increasing internationally, particularly in nations with historically low rates. Previous reports of the epidemiology of pediatric-onset IBD identified a paucity of data. We systematically reviewed t… Continue reading →

Hepatocellular carcinogenesis of hepatitis B virus (HBV) infection may arise from integration of viral DNA into the host genome. We aimed to gauge the effect of viral inhibition on transcriptionally active HBV-host integration events and explore the co… Continue reading →